DOCSLIB.ORG

Carcinoma, Carcinoma in Situ, and €Œearlylesions―Of the Uterine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Carcinoma, Carcinoma in Situ, and €Œearlylesions―Of the Uterine [CANCER RESEARCH 36. 2482-2484, July 1976] Carcinoma, Carcinoma in Situ, and “EarlyLesions―ofthe Uterine Cervix and the Urinary Bladder: Introduction and Definitions1 Gilbert H. Friedell Departments of Pathology, St. Vincent Hospital and University of Massachusetts Medical School, Worcester, Massachusetts 01610 At the outset of this combined session on “earlylesions― evident before calling the lesion cancer. Others have ac of the uterine cervix and the urinary bladder, I should like to cepted the terminological paradox of a ‘‘noninvasive propose some definitions as a basis for the discussions to cancer' ‘andhave used ‘‘superficialcarcinoma―or “carci follow. First of all, however, I would remind you how the noma in situ―when the markedly abnormal epithelium does pathologist gives meaningful names to morphological en not appear to penetrate the basement membrane when tities. Basically, there are 3 phases to naming such an en seen with the light microscope. I prefer the term carcinoma tity. in situ, and use the following definition. First, the pathologist applies a descriptive term to the Carcinoma in situ is epithelium that has the histological lesion so that all who hear the term or see it in print will features characteristic of cancer, but is noninvasive. It is know what the entity looks like. It is best if the term carries related in space or in time to the presence of carcinoma, with it neither pathogenetic nor prognostic implications, and will, if untreated, progress to carcinoma of the same since only a purely descriptive designation is appropriate at histological type in a significantly high percentage of cases. this stage. In the cervix, the spatial relationship between invasive In the 2nd phase, the natural history of the lesion in ques and noninvasive carcinoma was recognized almost a cen tion is studied. Clinicians and pathologists alike provide in tury ago by SirJohn Williams (19), was noted and illustrated formation concerning the behavior and biology of the in 1900 by Cullen (4), and was described in greater detail a morphological entity. few years later by others (12, 13, 15, 16). They all noted the When the clinical significance is known, when the natural presence of noninvasive but histologically malignant epi history of the lesion has been elucidated, we then enter thelium adjacent to carcinoma. It was Broders in 1932 (2) Phase 3 of the nomenclature sequence. A name is selected who first termed this epithelium carcinoma in situ. which will not only convey information about the morphol Subsequent cases were reported in which the presence ogy of the entity, but will also have pathogenetic and of such noninvasive malignant epithelium preceded by prognostic significance. The word “cancer,―forexample, months or years the development of invasive cervical when applied by the pathologist to a biopsy specimen, has cancer (6, 17). Gradually, this concept of a sequential grave prognostic significance and very definite therapeutic temporal relationship between the presence of carcinoma implications. One would be loathe to designate a prolifera in situ and the development of cervical carcinoma was ac tive epithelial lesion as ‘‘carcinoma'‘withouthard data con cepted. Based on data concerning the peak age incidence cerning the natural history of the entity in question. The of both in situ and Stage I carcinoma, it has been esti term carcinoma could be appropriately applied in Phase 3 mated that the progression of in situ to invasive carcinoma of the nomenclature sequence, but not in Phase 1. of the cervix takes an average of 10 years (6, 18). We would restrict the designation of carcinoma to those That such progression is not inevitable, however, was epithelial lesions that meet the histological criteria for clearly pointed out by the work of Dr. Olaf Petersen (11). malignancy, that invade the subepithelial or supporting Indeed, through personal communication with him and connective tissue, and that metastasize and/or kill the pa with Professor Johannes Clemmesen since 1960, it is clear tient (unless prevented from doing so by the introduction that, in some of Petersen's cases, carcinoma in situ has of appropriate treatment). Use of the term carcinoma not persisted —without either progressing or regressing —for only indicates that the prognosis is poor unless the patient many years, and may possibly do so through the remaining is treated appropriately, but it also implies that the user of lifetime of these patients. Others have also found that pro the term knows what the outcome will be. gression is not inevitable in untreated cases of carcinoma If we accept this definition of carcinoma, however, we in situ, and at this time it is probably fair to say that then have a problem in giving a name to the superficial carcinoma in situ of the cervix, if not treated, will progress lesion which histologically resembles carcinoma but does to carcinoma in some 50 to 60% of cases over a period of 5 not invade the subepithelial tissue. Some have suggested to 20 years. This is not to say that the lesion regresses “precancer―asa designation, waiting until invasion is spontaneously in 40 to 50% of cases, but simply that it does not progress in these cases. “Spontaneousdisappearance ‘Presented at the Conference. “Early Lesions and the Development of of carcinoma in situ apparently does occur, but it is an ex Epithelial Cancer,―October 21 to 23, 1975, Bethesda, Md. Development of this manuscript supported by USPHS Grant 15490 from the National Cancer traordinarily rare event―(9). Institute through the National Bladder Cancer Project. Thus, as we define carcinoma in situ of a given organ, it 2482 CANCER RESEARCHVOL. 36 Downloaded from cancerres.aacrjournals.org on October 1, 2021. © 1976 American Association for Cancer Research. Early Lesions of Uterine Cervix and Urinary Bladder becomes important to know just what constitutes a ‘‘sig without this stimulus, will not go on to carcinoma. Some nificantly high percentage of cases.―Ifwe take as a stand epithelial hyperplasias of the cervix and bladder would fall ard the 50 or 60% progression that we have just given for into this category of precursor or preneoplastic lesions. cervical carcinoma in situ, how many lesions now called Morphologically, the early and precursor lesions will be carcinoma in situ in other organs will meet this part of the similar, but the irreversibility of the 1st and reversibility definition? Suppose we find that in some organ a given of the 2nd would distinguish them biologically. A biochemi noninvasive lesion which histologically resembles carci cal, biological, or other marker would be most helpful in noma, if left untreated, will progress to carcinoma only in making this distinction. 15% of cases. Is this a sufficiently high figure to justify During this first conference session dealing with early the diagnosis of carcinoma in situ? If not, how should this lesions of the uterine cervix and the urinary bladder, there lesion be designated? As “precarcinomainsitu―?Another will be references made to experimental models. Such possibility, of course, is that we should have a sliding scale models may be defined as experimental systems, either for “significantlyhigh percentage of cases―so that we in vitro or in vivo, in which some aspect of the natural would diagnose carcinoma in situ in one organ if the figure history of a human cancer can be studied. Generally, the is 15 or 20%, while in another organ the diagnosis would model will be the growing tumor or the tumor interacting have a 70% figure attached to it. with the host, but it might also be the host itself, as in the The spatial and temporal relationship between nonin development of a model for screening carcinogenic com vasive and invasive carcinoma of the bladder is also clearly pounds. For example , a N-[4-(5-nitro-2-furyl)-2-thiazolyl]- evident. The study of giant tissue sections illustrates the formamide-induced bladder tumor in the Fischer rat might spatial relationship particularly well (1, 14). The temporal be a good model for the study of the pathogenesis of relationship has been shown by information from longitu human bladder cancer (3), but the Fischer rat itself might dinal studies of patients with bladder cancer (7, 8, 10). be a model for screening carcinogenic compounds. These studies indicate that an'in situ phase precedes the During this meeting we will be discussing models in development of invasive cancer in the bladder as it does in which tumor cell markers or the markers of host response the uterine cervix, but the in situ entity is less well defined to tumors (or early lesions) can be identified and followed. and the relationship between noninvasive flat and papillary A marker of an epithelial tumor, or of the epithelial cell com lesions remains to be worked out. Nevertheless, in many prising the early lesion is that structural or functional cellu ways the principles derived from the study of cervical carci lar characteristic which can be used to identify a tumor noma in situ would seem to be applicable, and the defini cell or the cellular components of an early lesion. The latter tions just given can probably be used as we discuss pro would be called early lesion markers and might include liferative lesions of the bladder (5). cytological, histological, or ultrastructural characteristics In studies of the cervix, attention has also been devoted of epithelial cells, or the identification of some product to characterizing the early lesion which precedes the de elaborated by the cells in question and detected locally or velopment of histologically recognizable carcinoma in situ. systemically. Terms applied to it include atypical hyperplasia, anaplasia, At the same time, we will be discussing host markers, dysplasia, and others.
Load more

Recommended publications
  • Genetic Markers in Lung Cancer Diagnosis: a Review
    International Journal of Molecular Sciences Review Genetic Markers in Lung Cancer Diagnosis: A Review Katarzyna Wadowska 1 , Iwona Bil-Lula 1 , Łukasz Trembecki 2,3 and Mariola Sliwi´ ´nska-Mosso´n 1,* 1 Department of Medical Laboratory Diagnostics, Division of Clinical Chemistry and Laboratory Haematology, Wroclaw Medical University, 50-556 Wroclaw, Poland; [email protected] (K.W.); [email protected] (I.B.-L.) 2 Department of Radiation Oncology, Lower Silesian Oncology Center, 53-413 Wroclaw, Poland; [email protected] 3 Department of Oncology, Faculty of Medicine, Wroclaw Medical University, 53-413 Wroclaw, Poland * Correspondence: [email protected]; Tel.: +48-71-784-06-30 Received: 1 June 2020; Accepted: 25 June 2020; Published: 27 June 2020 Abstract: Lung cancer is the most often diagnosed cancer in the world and the most frequent cause of cancer death. The prognosis for lung cancer is relatively poor and 75% of patients are diagnosed at its advanced stage. The currently used diagnostic tools are not sensitive enough and do not enable diagnosis at the early stage of the disease. Therefore, searching for new methods of early and accurate diagnosis of lung cancer is crucial for its effective treatment. Lung cancer is the result of multistage carcinogenesis with gradually increasing genetic and epigenetic changes. Screening for the characteristic genetic markers could enable the diagnosis of lung cancer at its early stage. The aim of this review was the summarization of both the preclinical and clinical approaches in the genetic diagnostics of lung cancer. The advancement of molecular strategies and analytic platforms makes it possible to analyze the genome changes leading to cancer development—i.e., the potential biomarkers of lung cancer.
    [Show full text]
  • DCIS): Pathological Features, Differential Diagnosis, Prognostic Factors and Specimen Evaluation
    Modern Pathology (2010) 23, S8–S13 S8 & 2010 USCAP, Inc. All rights reserved 0893-3952/10 $32.00 Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation Sarah E Pinder Breast Research Pathology, Research Oncology, Division of Cancer Studies, King’s College London, Guy’s Hospital, London, UK Ductal carcinoma in situ (DCIS) is a heterogeneous, unicentric precursor of invasive breast cancer, which is frequently identified through mammographic breast screening programs. The lesion can cause particular difficulties for specimen handling in the laboratory and typically requires even more diligent macroscopic assessment and sampling than invasive disease. Pitfalls and tips for macroscopic handling, microscopic diagnosis and assessment, including determination of prognostic factors, such as cytonuclear grade, presence or absence of necrosis, size of the lesion and distance to margins are described. All should be routinely included in histopathology reports of this disease; in order not to omit these clinically relevant details, synoptic reports, such as that produced by the College of American Pathologists are recommended. No biomarkers have been convincingly shown, and validated, to predict the behavior of DCIS till date. Modern Pathology (2010) 23, S8–S13; doi:10.1038/modpathol.2010.40 Keywords: ductal carcinoma in situ (DCIS); breast cancer; histopathology; prognostic factors Ductal carcinoma in situ (DCIS) is a malignant, lesions, a good cosmetic result can be obtained by clonal proliferation of cells growing within the wide local excision. Recurrence of DCIS generally basement membrane-bound structures of the breast occurs at the site of previous excision and it is and with no evidence of invasion into surrounding therefore better regarded as residual disease, as stroma.
    [Show full text]
  • Understanding Ductal Carcinoma in Situ (DCIS)
    Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre Funded by the Australian Government Department of Health and Ageing Understanding ductal carcinoma in situ Contents Acknowledgements .........................................................................................2 How to use this resource ..............................................................................3 Introduction ...........................................................................................................4 Why do I need treatment for DCIS? .........................................................5 Surgery ......................................................................................................................7 Radiotherapy ......................................................................................................11 What is the risk of developing invasive breast cancer or Understanding ductal carcinoma in situ (DCIS) and deciding about treatment was prepared and produced by: DCIS after treatment? ....................................................................................12 National Breast and Ovarian Cancer Centre What follow-up will I need? .......................................................................17 Level 1 Suite 103/355 Crown Street Surry Hills NSW 2010 How can I get more emotional support? .........................................18 Locked Bag 3
    [Show full text]
  • Surgical Management of Brain Tumors
    SURGICAL MANAGEMENT OF BRAIN TUMORS JASSIN M. JOURIA, MD DR. JASSIN M. JOURIA IS A MEDICAL DOCTOR, PROFESSOR OF ACADEMIC MEDICINE, AND MEDICAL AUTHOR. HE GRADUATED FROM ROSS UNIVERSITY SCHOOL OF MEDICINE AND HAS COMPLETED HIS CLINICAL CLERKSHIP TRAINING IN VARIOUS TEACHING HOSPITALS THROUGHOUT NEW YORK, INCLUDING KING’S COUNTY HOSPITAL CENTER AND BROOKDALE MEDICAL CENTER, AMONG OTHERS. DR. JOURIA HAS PASSED ALL USMLE MEDICAL BOARD EXAMS, AND HAS SERVED AS A TEST PREP TUTOR AND INSTRUCTOR FOR KAPLAN. HE HAS DEVELOPED SEVERAL MEDICAL COURSES AND CURRICULA FOR A VARIETY OF EDUCATIONAL INSTITUTIONS. DR. JOURIA HAS ALSO SERVED ON MULTIPLE LEVELS IN THE ACADEMIC FIELD INCLUDING FACULTY MEMBER AND DEPARTMENT CHAIR. DR. JOURIA CONTINUES TO SERVES AS A SUBJECT MATTER EXPERT FOR SEVERAL CONTINUING EDUCATION ORGANIZATIONS COVERING MULTIPLE BASIC MEDICAL SCIENCES. HE HAS ALSO DEVELOPED SEVERAL CONTINUING MEDICAL EDUCATION COURSES COVERING VARIOUS TOPICS IN CLINICAL MEDICINE. RECENTLY, DR. JOURIA HAS BEEN CONTRACTED BY THE UNIVERSITY OF MIAMI/JACKSON MEMORIAL HOSPITAL’S DEPARTMENT OF SURGERY TO DEVELOP AN E- MODULE TRAINING SERIES FOR TRAUMA PATIENT MANAGEMENT. DR. JOURIA IS CURRENTLY AUTHORING AN ACADEMIC TEXTBOOK ON HUMAN ANATOMY & PHYSIOLOGY. Abstract The field of brain tumor research, diagnosis, and treatment is rapidly evolving. Over 120 types of brain tumors have been identified to date, and that number continues to increase. As the information available about brain tumors grows, so does the ability to target screening and therapies to provide patients with optimal outcomes. It is critical that health clinicians understand the surgical and treatment options in order to educate patients and to develop a care plan that has a positive outcome while respecting the patient's needs and desires.
    [Show full text]
  • Full Text (PDF)
    Published OnlineFirst April 1, 2014; DOI: 10.1158/1940-6207.CAPR-13-0362 Cancer Prevention Research Article Research Inhibition of the Transition of Ductal Carcinoma In Situ to Invasive Ductal Carcinoma by a Gemini Vitamin D Analog Joseph Wahler1, Jae Young So1, Yeoun Chan Kim1, Fang Liu1,2,3, Hubert Maehr1, Milan Uskokovic1, and Nanjoo Suh1,3 Abstract Ductal carcinoma in situ (DCIS) is a nonmalignant lesion of the breast with the potential to progress to invasive ductal carcinoma (IDC). The disappearance and breakdown of the myoepithelial cell layer and basement membrane in DCIS have been identified as major events in the development of breast cancer. The MCF10DCIS.com cell line is a well-established model, which recapitulates the progression of breast cancer from DCIS to IDC. We have previously reported that a novel Gemini vitamin D analog, 1a,25-dihydroxy- 20R-21(3-hydroxy-3-deuteromethyl-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-cholecalciferol (BXL0124) is a potent inhibitor of the growth of MCF10DCIS.com xenografted tumors without hypercal- cemic toxicity. In this study, we utilized the MCF10DCIS.com in vivo model to assess the effects of BXL0124 on breast cancer progression from weeks 1 to 4. Upon DCIS progression to IDC from weeks 3 to 4, tumors lost the myoepithelial cell layer and basement membrane as shown by immunofluorescence staining with smooth muscle actin and laminin 5, respectively. Administration of BXL0124 maintained the critical myoepithelial cell layer as well as basement membrane, and animals treated with BXL0124 showed a 43% reduction in tumor volume by week 4.
    [Show full text]
  • Consensus Guideline on the Management of the Axilla in Patients with Invasive/In-Situ Breast Cancer
    - Official Statement - Consensus Guideline on the Management of the Axilla in Patients With Invasive/In-Situ Breast Cancer Purpose To outline the management of the axilla for patients with invasive and in-situ breast cancer. Associated ASBrS Guidelines or Quality Measures 1. Performance and Practice Guidelines for Sentinel Lymph Node Biopsy in Breast Cancer Patients – Revised November 25, 2014 2. Performance and Practice Guidelines for Axillary Lymph Node Dissection in Breast Cancer Patients – Approved November 25, 2014 3. Quality Measure: Sentinel Lymph Node Biopsy for Invasive Breast Cancer – Approved November 4, 2010 4. Prior Position Statement: Management of the Axilla in Patients With Invasive Breast Cancer – Approved August 31, 2011 Methods A literature review inclusive of recent randomized controlled trials evaluating the use of sentinel lymph node surgery and axillary lymph node dissection for invasive and in-situ breast cancer as well as the pathologic review of sentinel lymph nodes and indications for axillary radiation was performed. This is not a complete systematic review but rather, a comprehensive review of recent relevant literature. A focused review of non-randomized controlled trials was then performed to develop consensus guidance on management of the axilla in scenarios where randomized controlled trials data is lacking. The ASBrS Research Committee developed a consensus document, which was reviewed and approved by the ASBrS Board of Directors. Summary of Data Reviewed Recommendations Based on Randomized Controlled
    [Show full text]
  • EAU Guidelines on the Diagnosis and Treatment of Urothelial Carcinoma in Situ Adrian P.M
    European Urology European Urology 48 (2005) 363–371 EAU Guidelines EAU Guidelines on the Diagnosis and Treatment of Urothelial Carcinoma in Situ Adrian P.M. van der Meijdena,*, Richard Sylvesterb, Willem Oosterlinckc, Eduardo Solsonad, Andreas Boehlee, Bernard Lobelf, Erkki Rintalag for the EAU Working Party on Non Muscle Invasive Bladder Cancer aDepartment of Urology, Jeroen Bosch Hospital, Nieuwstraat 34, 5211 NL ’s-Hertogenbosch, The Netherlands bEORTC Data Center, Brussels, Belgium cDepartment of Urology, University Hospital Ghent, Ghent, Belgium dDepartment of Urology, Instituto Valenciano de Oncologia, Valencia, Spain eDepartment of Urology, Helios Agnes Karll Hospital, Bad Schwartau, Germany fDepartment of Urology, Hopital Ponchaillou, Rennes, France gDepartment of Urology, Helsinki University Hospital, Helsinki, Finland Accepted 13 May 2005 Available online 13 June 2005 Abstract Objectives: On behalf of the European Association of Urology (EAU), guidelines for the diagnosis, therapy and follow-up of patients with urothelial carcinoma in situ (CIS) have been established. Method: The recommendations in these guidelines are based on a recent comprehensive overview and meta-analysis in which two panel members have been involved (RS and AVDM). A systematic literature search was conducted using Medline, the US Physicians’ Data Query (PDQ), the Cochrane Central Register of Controlled Trials, and reference lists in trial publications and review articles. Results: Recommendations are provided for the diagnosis, conservative and radical surgical treatment, and follow- up of patients with CIS. Levels of evidence are influenced by the lack of large randomized trials in the treatment of CIS. # 2005 Elsevier B.V. All rights reserved. Keywords: Bladder cancer; Carcinoma in situ; Bacillus Calmette-Guerin; Chemotherapy; Diagnosis; Treatment; Follow up 1.
    [Show full text]
  • Carcinoma in Situ
    JPAC 13-65 Joint UKBTS Professional Advisory Committee (1) Summary Sheet 1. Paper for the JPAC meeting on: 14 November 2013 2. Date submitted: 31 October 2013 3. Title (including version no.): Carcinoma in Situ 4. Author(s): Dr Sue Barnes, Chair of the SAC on Care and Selection of Donors 5. Brief summary: The DSG allows the acceptance of a very limited number of donors diagnosed, treated and cured and only non- clonal premalignant disease. BSQR 2005 allows acceptance of donors with ‘in situ cancer with complete recovery’. The WHO recommends acceptance if ‘in situ carcinoma (e.g. BCC) has been successfully treated. The CoE recommends the donor may be accepted immediately after successful removal and cure. We are thus recommending a change to the current DSG entry for Malignancy to allow a wider range of carcinomas in situ to be accepted once cured and to clarify the position re premalignant conditions. 6. Action required by the JPAC: Discuss and approve recommendation (What do you want JPAC to do in response to this paper?) e.g. endorse a specific recommendation advise where there is a choice of possible actions advise on priorities within the work plan provide a steer on policy 7. Any other relevant information: (1) Joint United Kingdom Blood Transfusion Services Professional Advisory Committee Page 1 of 5 JPAC 13-65 Carcinoma in situ Background Carcinoma in situ (CIS) is an early form of cancer that is defined by the absence of invasion of tumor cells into the surrounding tissue, usually before penetration through the basement membrane.
    [Show full text]
  • Vulvar Cancer Causes, Risk Factors, and Prevention Risk Factors For
    cancer.org | 1.800.227.2345 Vulvar Cancer Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for vulvar cancer. ● Risk Factors for Vulvar Cancer ● What Causes Vulvar Cancer? Prevention There is no way to completely prevent cancer. But there are things you can do that might lower your risk. Learn more. ● Can Vulvar Cancer Be Prevented? Risk Factors for Vulvar Cancer A risk factor is anything that changes a person's chance of getting a disease such as cancer. Different cancers have different risk factors. For example, exposing skin to strong sunlight is a risk factor for skin cancer. Smoking is a risk factor for many cancers. There are different kinds of risk factors. Some, such as your age or race, can’t be 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 changed. Others may be related to personal choices such as smoking, drinking, or diet. Some factors influence risk more than others. But risk factors don't tell us everything. Having a risk factor, or even several, does not mean that a person will get the disease. Also, not having any risk factors doesn't mean that you won't get it, either. Although several risk factors increase the odds of developing vulvar cancer, most women with these risks do not develop it. And some women who don’t have any apparent risk factors develop vulvar cancer. When a woman develops vulvar cancer, it is usually not possible to say with certainty that a particular risk factor was the cause.
    [Show full text]
  • Predictors of Invasion and Axillary Lymph Node Metastasis in Patients with a Core Biopsy Diagnosis of Ductal Carcinoma in Situ: an Analysis of 255 Cases
    ORIGINAL ARTICLE Predictors of Invasion and Axillary Lymph Node Metastasis in Patients with a Core Biopsy Diagnosis of Ductal Carcinoma In Situ: An Analysis of 255 Cases Jeong S. Han, MD, PhD, Kyle H. Molberg, MD and Venetia Sarode, MD Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, Texas n Abstract: The diagnosis of ductal carcinoma in situ (DCIS) using core biopsy does not ensure the absence of invasion on final excision. We performed a retrospective analysis of 255 patients with DCIS who had subsequent excision. Clinical, radiologic, and pathologic findings were correlated with risk of invasion and sentinel lymph node (SLN) metastasis. Of 255 patients with DCIS, 199 had definitive surgery and 52 (26%) had invasive ductal carcinoma (IDC) on final excision. Extent of abnormal microcalcification on mammography, and presence of a radiologic ⁄ palpable mass and solid type of DCIS were significantly associated with invasion on final excision. Sentinel lymph node biopsy was performed in 131 (65.8%) patients of whom 18 (13.4%) had metastasis. Size of IDC and extent of DCIS on final pathology were significantly associated with positive SLN. Micrometastasis and isolated tumor cells comprised majority (71.4%) of the metastases in DCIS. SLN biopsy should be considered in those with high risk DCIS. n Key Words: Ductal carcinoma in situ, invasion, metastasis, sentinel lymph node biopsy uctal carcinoma in situ (DCIS) is a clonal prolif- require additional surgery, and accurate SLN mapping Deration of malignant cells confined to the ductal- could be compromised. On the other hand, for the lobular units without invading the periductal stroma.
    [Show full text]
  • Case Report Vaginal Primary Malignant Melanoma Complicating Cervical Carcinoma in Situ: a Case Report and Review of Literature
    Int J Clin Exp Pathol 2016;9(4):4555-4559 www.ijcep.com /ISSN:1936-2625/IJCEP0021903 Case Report Vaginal primary malignant melanoma complicating cervical carcinoma in situ: a case report and review of literature Fei-Fei Liu1, Quan Tian1, Yan Xue1, Mei-Li Pei1, Chun-Bao Wang2, Rui-Fang An1 Departments of 1Gynecology and Obstetrics, 2Pathology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shanxi, P. R. China Received December 14, 2015; Accepted February 25, 2016; Epub April 1, 2016; Published April 15, 2016 Abstract: Vaginal primary malignant melanoma (VPMM) is a rare and extremely aggressive tumor. Because of hid- den location and lack of early symptoms, it usually develops at advanced stage and has very high mortality rate. Moreover, the etiology of this tumor is largely unknown. Therefore, it is important for improving prognosis to early diagnosis of VPMM. In the present study, we describe a 35-year-old female patient who was diagnosed as VPMM combined with CIN3 before any report not mentioned. The patient presented to our hospital with abnormal vaginal bleeding of 2 months. Preoperative colposcopic-directed biopsy and physical examination suggested malignant le- sions occurred in the upper third of anterior vaginal wall. Then a wide local excision of the lesion was first performed. Postoperative pathological results confirmed and metastasis to left internal iliac lymphnodes. She underwent adju- vant radiotherapy and immunotherapy as further therapeutic measures. Although the patient could not complete a cycle due to intolerable toxicity of immunotherapy, she is still alive 14 months after diagnose. Keywords: VPMM, etiology, treatment, surgery, radiotherapy Introduction cm diameter in the upper third of anterior vagi- nal wall.
    [Show full text]
  • TUMOR and STAGING DATA Cont. AJCC TNM Staging
    TUMOR and STAGING DATA cont. Extensive material in this section comes with permission from the AJCC Cancer Staging Manual, Sixth Edition, Springer-Verlag, New York 2002. See the Permissions page. AJCC TNM Staging System At this time, it is the COC's plan to continue collection of "manual" TNM staging even after Collaborative Staging goes into effect. The MCR now plans to NOT collect these fields for diagnoses made beginning in 2004. The AJCC staging fields are all required for pre-2004 diagnoses for the MCR. Cases diagnosed beginning in 2003 are TNM-staged using the AJCC Cancer Staging Manual, Sixth Edition (with updates). The codes used to record the staging information can be found in the FORDS Manual and this MCR Manual. Both the staging manual and a coding manual must be used to record AJCC staging fields. Both clinical and pathologic staging fields are collected by the MCR. If you have enough information to specifically stage a case clinically and pathologically, then both stages should be specifically reported. The FORDS Manual, on its p. 23, and the AJCC Cancer Staging Manual, Sixth Edition note that both clinical and pathologic staging should be recorded. Use the codes for "unknown" and "not applicable" to complete the staging fields whenever appropriate. Some physicians seem to feel that a case with an unknown stage (for example, only an incisional biopsy of the primary tumor has been done) "cannot be staged"; everyone should be aware that a case with a correct "unknown" or "not applicable" stage assignment has been staged and can be recorded with appropriate codes (that do not appear in the Cancer Staging Manual).
    [Show full text]